The FDA has approved a new drug for patients with ALK-positive lung cancer. The drug is called brigatinib (brand name: Alunbrig) and is approved for treatment of patients whose tumor has the ALK mutation. Brigatinib is to be used after another drug targeting ALK stops working. The FDA press release is here: fda.gov/Drugs/InformationOn... This is great news as it gives patients with the ALK mutation another treatment option.